Please ensure Javascript is enabled for purposes of website accessibility

Why Invitae Was Down 17.5% in May

By Jason Hawthorne - Jun 8, 2021 at 3:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The genetic testing company's growth isn't the kind that impresses Wall Street.

What happened

Shares of Invitae (NVTA -8.05%) fell 17.5% in May, according to data provided by S&P Global Market Intelligence. Investors were not impressed with the company's first-quarter earnings early in the month, especially management's inability to control costs.

So what

The reaction may have surprised some who saw an accelerating top line as a sign of momentum in the business. Revenue came in at $103.6 million, up 61% from last year. That was higher than the 58% reported in the first quarter of 2020. Billable volume also accelerated, climbing 72% compared with 64% in the year-ago period. Unfortunately, that growth isn't proving that the company will scale to profitability, and it is coming at a steep price.

Lab workers with goggles are looking at samples in test tubes.

Image source: Getty Images.

The gross margin -- the percentage of revenue left over after the costs of sales -- was 27% compared with 37% last year. Even adjusting for acquisitions and stock-based compensation, this year's margin was lower than in 2020. That means despite performing more tests, the cost per test didn't go down. It's a red flag for Wall Street. Exacerbating the issue was the increase in shares outstanding.

At the end of March, Invitae had 194 million shares outstanding. That's almost twice the 99.6 million at the end of last year. Doing the math, each share represented $0.65 of sales and $0.27 of adjusted gross profit last year. Fast-forward to this year, and those numbers stood at $0.53 and $21, respectively. The ballooning share count also doesn't include the $1.15 billion in convertible debt the company raised in April. That isn't a concern for now. Even if they are converted, it would happen sometime in mid-2025 or later, and only if the stock remains at a price nearly 120% higher than it trades today.

Now what

Some say every dark cloud has a silver lining. Invitae shareholders might have to squint to see it. The massive share dilution and debt offerings have given the company a much-needed cash cushion. It ended March with $682 million on its balance sheet compared with just $301 million at the time last year. That's good because the company burned $299 million in 2020.

Management blamed the increasing costs on the timing of billing customers, as well as inefficient processing of newer tests. Timing should sort itself out through the remainder of the year. As for efficiency, that remains to be seen. Proving it can get costs in line will be the key to becoming self-funding. If it can, it should put Wall Street's mind at ease and get the shares moving up again.

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Invitae. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Invitae Stock Quote
Invitae
NVTA
$3.54 (-8.05%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.